Expression levels of CK20 were higher by trend in patients with late-stage tumor burden (median: 2.49 [EU], range: 0–118.00 [EU]) compared to patients with less advanced disease (median: 0 [EU], range: 0–22.90 [EU]), however, not allowing a clear discrimination from IID patients (all p = ns) (Figure 3A). Here, KRT20 is linked to neoplasm.